Diana Moore Appointed as Director, Investor Relations & Business Development at Advaxis, Conrad Mir Departs

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has appointed Diana Moore as Director, Investor Relations & Business Development.

Diana is a graduate of Princeton University where she was a Stanley J. Seeger Fellow in Hellenic Studies. Additionally, Diana holds a Masters of Contemporary Art from University of Manchester, UK where she graduated with distinction. Her thesis concentrated on the Public Perception of Biotechnology in Contemporary Art & Literature.

Prior to joining Advaxis, Ms. Moore conducted fund raising efforts for several non-profits including the D&R Greenway Land Trust where she currently curates their art galleries.

Diana has spent two years working at Advaxis in a number of capacities and has developed a keen understanding of the Company’s technology and has been able to combine that knowledge with her strong communications skills. She is also a member of the National Investor Relations Institute.

Conrad Mir has left Advaxis to pursue new interests. "We are grateful for his many contributions. Conrad worked hard to build Advaxis’ share ownership and share volume during one of the most difficult times for the economy in general and biotech in particular. He helped raise millions of dollars and provided both valuable service and access to many new investors. We deeply appreciate and thank Conrad for all his efforts,” said Tom Moore, Chairman and CEO.

Going forward Diana will focus on Investor Relations and Corporate Communications and report to Mark Rosenblum, the Company’s Chief Financial Officer. Mr. Moore and Mr. Rosenblum will concentrate on fundraising activities and commercial collaborations.

"Diana continues to refine our communications platform. Among other projects, she is leading the creation of a new "Chairman's Blog" written by Tom Moore and other members of the Advaxis team, to talk about the field of immunotherapy and Advaxis’ technology. It will be posted on our website in the coming weeks,” commented Rosenblum.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.